of the italian cancer society -...

Annual Meeting of theItalian Cancer Society

55th

:understanding onc-OMICS

for patient-tailored cancer therapy

In collaboration with:

Catanzaro23 – 26 September 2013


55th




1

CONGRESS VENUEUniversità degli Studi “Magna Græcia”

di CatanzaroViale Europa - 88100 Germaneto - Catanzaro

Villaggio Guglielmo Congress CenterPiazza Susanna, 1 - 88069 Copanello - Catanzaro

www.villaggioguglielmo.it

ORGANIZING SECRETARIAT

Adria Congrex SrlVia Sassonia, 30 – 47922 Rimini RN

Ph. +39 0541 305811 – Fax +39 0541 305842E-mail: [email protected]

Web site: www.adriacongrex.it/sic2013

SIC SECRETARIAT

Società Italiana di CancerologiaVia G. Venezian, 1 – 20133 Milan

Ph. +39 02 2666895 – Fax +39 02 2664342E-mail: [email protected] site: www.cancerologia.it

1

Welcome Address

Dear Members of SIC, Colleagues and Friends,

It is our great pleasure to welcome you in Catanzaro for the 55th Annual Meeting of the Italian Cancer Society (SIC).

The title of the 2013 meeting is “Welcome to the South - Understanding Onc‐OMICS for Patient‐Tailored Cancer Therapy”. This

title echoes a popular series of movies and underlines the fact that this conference is the first SIC Meeting to be held in Calabria.

In addition to its wealth of natural beauty and of history, this Region hosts one of the youngest and most dynamic Universities in

Italy, the University Magna Græcia of Catanzaro, strongly commitment to bio-medical research and in particular to translational

cancer research. The recently-established University Campus “S. Venuta”, where the inaugural session will be held, is a modern,

residential campus equipped with state-of-art facilities for cell biology, functional genomics and proteomics, bio-computing and

drug design, and for pre-clinical studies in animal models of disease.

The 2013 Meeting will be focused on highly relevant and timely topics including: Non-coding RNAs, Cancer Biochemistry and

Metabolism, Cancer Genomics and Epigenomics, Cancer Stem Cells, Animal Modelling of Cancer, Advanced Diagnostics and

Therapeutics.

The basic goal of this meeting is to highlight how world-wide efforts to catalogue mutations in multiple cancer types are underway

and discuss whether and how this may lead to novel discoveries that will be translated into new diagnostic tools, prognostic

indicators and therapeutic targets. There will be plenary lectures and presentations from top Italian and international experts in

the field of cancer, together with those given by young scientists, and focused breakthrough sessions particularly dedicated to

a comprehensive update on the most recent laboratory and clinical developments in the field of cancer. Traditional SIC events

will be the “Giorgio Prodi” memorial lecture, and the joint session with the Italian Association of Medical Oncology (AIOM), to

highlight the connection between basic research and new therapeutic approaches. The opening lecture will be held by Daniel

Peeper, and the closing lecture by John Quackenbush. Our Society continues to encourage the young investigators with initiatives

aimed at improving their professional growth and qualification. In this respect, the Meeting will dedicate to young scientists four

poster discussion sessions focusing on highly relevant topics, the “Piero Trivella” and EACR Prizes for the best posters, the “Elena

Cappannini” Award for the best publication, the Pezcoller Foundation scholarship, as well as travel grants and formative credits.

We thank you for your participation, and hope that this Meeting will be most enjoyable and productive for everybody.

Giuseppe Viglietto Riccardo Dolcetti Scientific Coordinator SIC President

3


55th




WITH THE AUSPICES OF:

Fondazione per la Ricercae la Cura dei Tumori

“Tommaso Campanella”

University of Magna GraeciaCatanzaro

Centro interdipartimentale di genomica e patologia molecolare

2

3

Committee

SIC SCIENTIFIC BOARD

PresidentRiccardo Dolcetti (CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy)

President ElectSilvia Giordano (Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy)

BoardAnna Bagnato (Regina Elena National Cancer Institute, Rome, Italy)Vincenzo Bronte (University of Verona, Italy)Maurizio D’Incalci (“Mario Negri” Institute for Pharmacological Research, Milan, Italy)Nicola Normanno (National Cancer Institute “G. Pascale”, Naples, Italy)Salvatore Pece (IFOM-IEO Campus, University of Milan, Italy)Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy)Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy)Stefania Tommasi (National Cancer Centre “Giovanni Paolo II”, Bari, Italy)Giuseppe Viglietto (University Magna Græcia, Catanzaro, Italy)

Past PresidentAlfredo Fusco (“Federico II” University, Naples, Italy)

Representative for Young ResearchersChiara Gabellini (Regina Elena National Cancer Institute, Rome, Italy)Pierlorenzo Pallante (Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy)

SCIENTIFIC AND ORGANIZING COMMITTEE

Scientific CoordinatorGiuseppe Viglietto (University Magna Græcia, Catanzaro, Italy)

Local Scientific CommitteeGennaro Ciliberto (National Cancer Institute “G. Pascale”, Naples, Italy; University Magna Græcia, Catanzaro, Italy)Francesco Saverio Costanzo (University Magna Graecia, Catanzaro, Italy)Gianni Cuda (University Magna Græcia, Catanzaro, Italy)Dolores Di Vizio (Cedars Sinai Medical Center, Los Angeles, CA, USA)Marcello Maggiolini (University of Cosenza, Italy)Giovanni Morrone (University Magna Græcia, Catanzaro, Italy)Pierosandro Tagliaferri (University Magna Græcia, Catanzaro, Italy)Pierfrancesco Tassone (University Magna Græcia, Catanzaro, Italy)

4


55th




5

Faculty

Valter Agosti University Magna Græcia, Catanzaro, ItalyPaolo Ascierto National Cancer Institute “G. Pascale”, Naples, ItalyAnna Bagnato Regina Elena National Cancer Institute, Rome, ItalyRosa Bernardi IRCCS San Raffaele Hospital, Milan, ItalyRenzo Canetta Bristol-Myers Squibb, Wallingford, CT, USAUgo Cavallaro European Institute of Oncology, Milan, ItalyPaola Chiarugi University of Florence, ItalyGennaro Ciliberto National Cancer Institute “G. Pascale”, Naples, Italy; University Magna Græcia, Catanzaro, ItalyPierpaolo Correale University of Siena, Italy Giovanni Cuda University Magna Græcia, Catanzaro, ItalyDonatella Del Bufalo Regina Elena National Cancer Institute, Rome, ItalyFrancesca Demichelis University of Trento, ItalySimona De Summa National Cancer Centre “Giovanni Paolo II”, Bari, ItalyMaurizio D’Incalci “Mario Negri” Institute for Pharmacological Research, Milan, ItalyFederica Di Nicolantonio Institute for Cancer Research and Treatment, Candiolo, Turin, ItalyDolores Di Vizio Cedars Sinai Medical Center, Los Angeles, CA, USARiccardo Dolcetti CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, ItalyGiulio Draetta MD Anderson Cancer Center, Houston, TX, USAManuela Ferracin University of Ferrara, ItalyRiccardo Fodde Josephine Nefkens Institute Erasmus University Medical Centre, Rotterdam, The NetherlandsNiels Frandsen Exiqon, Vedbaek, DenmarkGuido Franzoso Imperial College, London, United KingdomAlfredo Fusco Federico II University, Naples, ItalyCecilia Garofalo IRCCS Rizzoli Orthopaedic Institute, Bologna, ItalySilvia Giordano Institute for Cancer Research and Treatment, University of Turin, Candiolo, ItalyEric Holland Memorial Sloan Kettering Cancer Center, New York, NY, USAAntonio Iavarone Columbia University, New York, NY, USAJeffrey J. Legos GlaxoSmithKline, Collegeville, PA, USAMarco Macagno University of Turin, ItalyNorman J. Maitland University of York, United KingdomMaria Caterina Mione Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, GermanyAndrea Morandi University of Florence, ItalyGiovanni Morrone University Magna Græcia, Catanzaro, ItalyNicola Normanno National Cancer Institute “G. Pascale”, Naples, ItalyGiorgio Parmiani IRCCS San Raffaele Hospital, Milan, ItalyDaniel Peeper The Netherlands Cancer Institute, Amsterdam, The NetherlandsJohn Quackenbush Dana-Farber Cancer Institute, Boston, MA, USALucia Ricci Vitiani ISS, Istituto Superiore di Sanità, Rome, ItalyMercedes Robledo Spanish National Cancer Centre (CNIO), Madrid, SpainMark A. Rubin Weill Cornel Medical College, New York, NY, USAMassimo Santoro Federico II University, Naples, ItalyAldo Scarpa University of Verona, ItalyJan J. Schuringa Faculty of Medical Sciences, Hematology, Groningen, The NetherlandsKatia Scotlandi IRCCS Rizzoli Orthopaedic Institute, Bologna, ItalySalvatore Siena Niguarda Ca’ Granda Hospital, Milan, ItalyFrank J. Slack Yale University, New Haven, CT, USAGabriella Sozzi IRCCS National Cancer Institute, Milan, ItalyHenk J. Stunnenberg Nijmegen Centre for Molecular Life Sciences, Nijmegen, The NetherlandsPierosandro Tagliaferri University Magna Græcia, Catanzaro, ItalyPierfrancesco Tassone University Magna Græcia, Catanzaro, ItalyStefania Tommasi National Cancer Centre “Giovanni Paolo II”, Bari, ItalyGiancarlo Vecchio Federico II University, Naples, ItalyGiuseppe Viglietto University Magna Græcia, Catanzaro, ItalyStefano Volinia University of Ferrara, Italy

4 5

Programme at a glance

Monday, September 23th - University of Catanzaro13:00 Registration

14.00-14.30 Opening ceremony14.30-15.30 Opening lecture15.30-17.30 NON CODING RNAS18.00-19.30 CANCER BIOCHEMISTRY AND METABOLISM

19.30 Welcome cocktail

Tuesday, September 24th - Villaggio Guglielmo07:30 Registration

08.00-09.00 Meet the expert: informal round table@breakfast 09.00-13.00 CANCER GENOMICS AND EPIGENOMICS10.30.11.00 Coffee break12.30-13.15 ADVANCED OMIC TECHNOLOGIES IN CANCER RESEARCH13.15-14.15 Lunch14.15-16.20 Poster viewing with the presence of Authors16.20-19.10 ADVANCED DIAGNOSTICS AND THERAPEUTICS17.20-17.50 Coffee break19.20-20.20 Meeting of the SIC young investigators

Wednesday, September 25th - Villaggio Guglielmo08.00-09.00 Meet the expert: informal round table@breakfast 09.00-10.20 Poster Discussion 1A - 1B10.20.10.40 Coffee break10.40-11.40 Giorgio Prodi lecture11.40-13.00 Poster viewing with the presence of Authors13.00-14.00 Lunch14.00-15.20 Poster Discussion 2A - 2B15.30-18.30 CANCER STEM CELLS18.30-19.00 AWARD CEREMONY19.00-20.00 SIC General Assembly

20.30 Social Dinner

Thursday, September 26th - Villaggio Guglielmo08.15-12.30 ANIMAL MODELS OF CANCER9.45-10.15 Coffee break

12.30-13.30 Closing lecture13.30-13.45 Award for the best oral selected presentation13.45-14.00 Closing remarks14.00-15.00 Lunch

6


55th




7

13.00 Registration

14.00 ‐ 14.30 OPENING CEREMONY

GREETINGS FROM THE AUTHORITIES A. Quattrone (Magnifico Rettore Magna Graecia University, Catanzaro, Italy) R. Dolcetti (SIC President, Aviano PN, Italy)

GREETINGS FROM EACR D. Del Bufalo (EACR Executive Committee Member, Regina Elena National Cancer

Institute, Rome, Italy)

14.30 ‐ 15.30 OPENING LECTURE Chair: R. Dolcetti (Aviano PN, Italy)

Function-based screening for therapeutic targets in cancer D. Peeper (Amsterdam, The Netherlands) Sponsored by EACR

15.30 - 17.30 NON CODING RNAS Chairmen: S. Giordano (Turin, Italy) - P. Tassone (Catanzaro, Italy)

15.30 - 16.00 MicroRNAs as targeted therapeutics and therapeutic targets in cancer F.J. Slack (New Haven, USA)

16.00 - 16.30 MicroRNA and lung cancer G. Sozzi (Milan, Italy)

16.30 - 17.00 Role of MicroRNAs in progression and invasiveness of breast cancer S. Volinia (Ferrara, Italy)

17.00 - 17.15 The role of miRNAS in regulating angiogenesis C25 in BRCA related breast cancer K. Danza (IRCCS-National Cancer Center “Giovanni Paolo II”,Bari, Italy), S. De Summa, B. Pilato, R. Lacalamita, O. Popescu, R. Lambo, M. Carella, S. Tommasi

17.15 - 17.30 miRNA landscape in Stage I Epithelial Ovarian Cancer C29 defines the histotype specificities L. Paracchini (Mario Negri Institute for Pharmacological Research, Milan, Italy), E.

Calura, L. Zanotti, R. Fruscio, M. Di Marino, L. Beltrame., R. Baldo R., S. Magni, A. Ravaggi, E. Bignotti, G. Tognon, E. Sartori, S. Pecorelli, D. Katsaros, M. D’ Incalci,

C. Romualdi, S. Marchini

Monday 23 September SCIENTIFIC PROGRAMME

Venue: uniVersity of Catanzaro, auditorium

6 7

Monday 23 September SCIENTIFIC PROGRAMMEVenue: uniVersity of Catanzaro, auditorium

18.00 ‐ 19.30 CANCER BIOCHEMISTRY AND METABOLISM Chairmen: G. Cuda (Catanzaro, Italy) - G. Vecchio (Naples, Italy)

18.00 - 18.30 Cancer-selected targeting of the NF-ĸB pathway G. Franzoso (London, UK)

18.30 - 19.00 Reciprocal metabolic deregulation of tumors and their stroma P. Chiarugi (Florence, Italy)

19.00 - 19.15 Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune F2 C-terminal interaction M. Carotenuto, P. De Antonellis, L. Liguori, D. Spano, A. M. Bello, V. Ferrucci, A. Alonzi,

D. Magliulo, C. M. Chiarolla, S. Di Somma, N. Aiese, M. Zollo (CEINGE, Naples, Italy)

19.15 - 19.30 The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting G7 succinate dehydrogenase

A. Rasola (University of Padua, Italy)

19.30 Welcome cocktail

21.30 Shuttle Bus from the University to Villaggio Gugliemo

8


55th




9

Tuesday 24 September SCIENTIFIC PROGRAMME

Venue: Villaggio guglielmo

7.30 Registration

8.00 ‐ 9.00 MEET‐THE‐EXPERT: INFORMAL ROUND‐TABLE@BREAKFAST Parallel Sessions AnimAl models E. Holland (New York, USA) - M. Mione (Eggenstein-Leopoldshafen, Germany) CAnCer stem Cells N. Maitland (York, United Kingdom) - R. Fodde (Rotterdam, The Netherlands)

9.00 ‐ 13.00 CANCER GENOMICS AND EPIGENOMICS Chairmen: K. Scotlandi (Bologna, Italy) - S. Tommasi (Bari, Italy)

9.00 - 9.30 The drivers of oncogenesis and master regulators of glioblastoma A. Iavarone (New York, USA)

9.30 - 10.00 Next generation histopathological diagnosis: from genomics to clinical application A. Scarpa (Verona, Italy)

10.00 - 10.30 From OMIC to the patient M. Robledo (Madrid, Spain)

10.30 - 11.00 Coffee Break

11.00 - 11.30 Molecular archeology from next generation explorations F. Demichelis (Trento, Italy)

11.30 - 12.00 Detection of genetic and epigenetic alterations in plasma circulating tumor DNA F. Di Nicolantonio (Turin, Italy)

12.00 - 12.15 A massive parallel sequencing approach in a selected hereditary C19 breast/ovarian cancer serie highlights ATM as an important breast cancer

predisposing A. Buffone, A. Coppa (Sapienza University of Rome, Italy), S. Casadei, A. Prodosmo, V. Colicchia, A. Nicolussi, S. D’Inzeo, S. Brizi, S. Soddu, G. Giannini

12.15 - 12.30 Estrogen receptor BETA/AGO2 complex binds to breast cancer cell genome H20 and mediates transcriptional gene regulation by the nuclear receptor

R. Tarallo (University of Salerno, Baronissi,Italy), G. Nassa, G. Giurato, G. Bruno, A. Salvati, L. Ricciardi T. Rocco, F. Rizzo, A. Weisz

8 9

Tuesday 24 September SCIENTIFIC PROGRAMMEVenue: Villaggio guglielmo

12.30 - 13.15 ADVANCED OMIC TECHNOLOGIES IN CANCER RESEARCH Chairmen: G. Viglietto (Catanzaro, Italy) - G. Cuda (Catanzaro, Italy)

How to implement therapeutic drug monitoring through mass spectrometry in oncology

B. Casetta (AbSciex)

Somatic variant screening in solid tumors with ion torrent semiconductor sequencing

R. Tanzi (Life Technologies)

Illumina solutions for cancer analysis N. Cirenei (Product Marketing Manager Europa Illumina)

Initiatives in translational cancer research in Calabria: brief presentation of the PON- and POR-funded projects

A. Lidonnici (Biomedpark – HEMMAS)

13.15 - 14.15 Lunch

14.15 ‐ 16.20 POSTER VIEWING WITH THE PRESENCE OF THE AUTHORS

16.20 – 19.10 ADVANCED DIAGNOSTICS AND THERAPEUTICS

THE PHARMA’S VIEW Chairmen: G. Ciliberto (Naples, Italy) - M. D’ Incalci (Milan, Italy)

16.20 - 16.40 LNA antisense oligonucleotides: promising drug development platform and antisense tools for the study of RNA function in animals

N. Frandsen (Exiqon, Vedbaek, Denmark)

16.40 - 17.00 Challenges of drug discovery and development in the era of precision medicine

J.J. Legos (GSK, Collegeville, USA)

17.00 - 17.20 Immuno-oncology as a new modality of cancer treatment: research and development

R. Canetta (BMS, Wallingford, USA)


THE CLINICIANS’ VIEW – Joint Meeting SIC-AIOM Chairmen: N. Normanno (Naples, Italy) - P. Tagliaferri (Catanzaro, Italy)

17.50 - 18.10 Targeted drugs for melanoma P. Ascierto (Naples, Italy)

18.10 - 18.30 Targeted drugs for colon carcinoma S. Siena (Milan, Italy)

18.30 - 18.50 Combined immuno and chemotherapy/targeted therapy strategies G. Parmiani (Milan, Italy) Sponsored by EACR

18.50 - 19.10 Colon cancer chemoimmunotherapy from bench to bedside P. Correale (Siena, Italy)

19.20 - 20.20 MEETING OF SIC YOUNG INVESTIGATORS

10


55th




11

Wednesday 25 September SCIENTIFIC PROGRAMME


8.00 ‐ 9.00 MEET‐THE‐EXPERT: INFORMAL ROUND‐TABLE@BREAKFAST Parallel Sessions Cancer Genomics A. Iavarone (New York, USA) - M.A. Rubin (New York, USA) Non‐Coding RNAs F.J. Slack (New Haven, USA ) Oncometabolics P. Chiarugi (Florence, Italy)

9.00 ‐ 10.20 POSTER DISCUSSION 1: Parallel Sessions

9.00 ‐ 10.20 Poster Discussion 1A Sala Cassiodoro CANCER GENETICS, EPIGENETICS AND CONTROL OF GENE EXPRESSION Chairmen: S. De Summa (Bari, Italy) - G. Viglietto (Catanzaro, Italy)

E5 Critical role of zinc finger protein 521 in the control of growth and tumourigenicity of human medulloblastoma cells

R. Spina, G. Filocamo, E. Iaccino, S. Scicchitano (University of “Magna Graecia”,Catanzaro, Italy), M. Lupia, E. Chiarella, T. Mega,F. Bernaudo, D. Pelaggi, M. Mesuraca, S. Pazzaglia, S. Semenkow, E.E. Bar, M. Kool,S. Pfister, H.M. Bond, C.G. Eberhart , C. Steinkuhler, G. Morrone

E17 CXCR4 inhibition impairs stemness features and blocks the metastatic dissemination induced by chemotherapy of migrating lung cancer initiating cells G. Bertolini (IRCCS National Cancer Institute, Milan, Italy), M. Moro, M. Tortoreto, D. Wong, L. Gatti, R. Caserini, U. Pastorino, L. Roz,G. Sozzi

C20 ATM protein kinase promotes HER2-dependent tumorigenesisV. Stagni (IRCCS-Fondazione Santa Lucia, Rome, Italy), V. Oropallo, M. Antonelli, R. Falcioni, A. Di Benedetto, M. Mottolese, D. Barila

C23 SEMA6A and MICAL-1 sustain cell growth and survival of BRAF mutant human melanomaR. Loria, V. Perrotti, G. Bon, P. Baldassarri, I. Bersani, S. Rossi, R. Mortarini, A. Anichini, R. Falcioni (National Cancer Institute Regina Elena, Rome, Italy)

H17 Histone deacetilase inhibitors repress the expression of the pro-invasive factor Runx2, in tumor cells, through a new intronic enhancer region V. Sancisi, G. Gandolfi, G. Damia, D. Ambrosetti, A. Ciarrocchi (Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia, Italy)

H4 MEF2 is a converging hub for HDAC4 and PI3K/Akt-induced transformationE. Di Giorgio (University of Udine, Italy), A. Clocchiatti, A. Sgorbissa, E. Gagliostro, C. Brancolini

H3 Study of ADAR2 editing enzyme in astrocytoma proliferation A. Gallo (Ospedale Pediatrico Bambino Gesù IRCCS, Rome Italy), S. Tomaselli, F. Galeano, F. Locatelli

E16 ERK5-inhibition as a novel approach to target CML stem cellsE. Rovida (University of Florence, Italy), I. Tusa, G. Cheloni, N.S. Gray, X. Deng, P. Dello Sbarba

10 11

H21 Silencing of the collagen prolyl hydroxylases is associated with metastatic breast cancer and metastatic melanomaC. Lo Nigro (S. Croce General Hospital, Cuneo, Italy), H. Wang, L. Lattanzio, M. Monteverde, N. Syed, O. Garrone, M. Occelli, E. Hatzimichael, M. Merlano, C. Proby, A. Thompson, T. Crook

9.00 ‐ 10.20 Poster Discussion 1B Sala Ibico TUMOR IMMUNOLOGY AND MICROENVIRONMENT Chairmen: A. Bagnato (Rome, Italy) - M. Macagno (Turin , Italy)

U3 Effects induced by miR-29b on Multiple Myeloma (MM)-related immunological microenvironmentC. Botta (University of “Magna Graecia”, Catanzaro, Italy), M. Rossi, M. R. Pitari, T. Del Giudice, A. Gullà, E. Morelli, L. Biamonte, N. Amodio, M. T. Di Martino, M. Ventura, P. Correale, P. Tagliaferri, P. Tassone

U4 Exploiting immunogenic cancer cell death to improve dendritic cell-based immunotherapyJ. Dal Col (CRO-IRCCS, Aviano PN; Italy), D. Martorelli, B. Montico, K. Mastorci, E. Comaro, R. Dolcetti

B2 Role of senescent stroma in prostate cancer progressionM. L. Taddei (University of Florence, Italy), G. Comito, L. Cavallini, E. Giannoni, P. Chiarugi

F20 L-proline induces a mesenchymal like invasive program in embryonic stem cells by remodelling H3K9 and H3K36 methylationS. Comes, M. Gagliardi, N. Laprano, A. Fico, A. Cimmino, A. Palamidessi, C. Angelini, S. De Falco, G. Scita, E.J. Patriarca, M. R. Matarazzo, G. Minchiotti (Institute of Genetics and Biophysics “A. Buzzati-Traverso”, CNR, Naples, Italy)

F6 CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce the incidence of tumor spreading and improve overall survival in preclinical models of prostate cancerG. L. Gravina, M. Tortoreto, A. Mancini, P. Muzi, L. Ventura, A. Addis, Y. Landesman, D. McCauley, M. Kauffman, S. Shacham, N. Zaffaroni, C. Festuccia (University of L’Aquila, Italy)

F9 Acidic microenvironment drives melanoma progression through cell to cell sustained exosome-mediated transfer of metastatic moleculesZ. Boussadia (Istituto Superiore di Sanità, Rome, Italy), I. Parolini, F. Felicetti, C. Coscia, S. Camerini, C. Zanetti, A. De Feo, L. Pasquini, M. Biffoni, A. Carè, M. Sargiacomo

F3 Characterization of transgenic mouse model and derivative cells line of SCLC induced by HPV-16 E6/E7R. Martinelli (University of Salerno, Baronissi, Italy), S.L. Nori, F. De Caro, G. Boccia, M. Capunzo

Wednesday 25 September SCIENTIFIC PROGRAMMEVenue: Villaggio guglielmo

12


55th




13

U11 Development of human bispecific antibodies against CD20/CD55 and CD20/59 for the treatment of B-cell disordersP. Macor (University of Trieste, Italy), E. Secco, N. Mezzaroba, S. Zorzet, P. Durigutto, T. Gaiotto, F. Ziller, L. De Maso, S. Biffi, S. Capolla, M. Calvaruso, C. Tripodo, C. Garrivo, V. Gattei, R. Marzari, F. Tedesco, D. Sblattero

V8 Gelatinases promote progression and metastasis in leiomyosarcoma in vitro and in vivoC. Alias, A. D’Angelo (Azienda Ospedaliero-Universitaria, Parma, Italy), L. Rocchi, S. Caraffi, R. Perris, D. Mangieri


10.40 ‐ 11.40 GIORGIO PRODI LECTURE

Introduction: R. Dolcetti (Aviano PN, Italy)

From RET oncogene identification in thyroid cancer to targeted therapy M. Santoro (Naples, Italy)

11.40 ‐ 13.00 POSTER VIEWING WITH THE PRESENCE OF AUTHORS

13.00 - 14.00 Lunch

14.00 ‐ 15.20 POSTER DISCUSSION 2: Parallel Sessions

14.00 ‐ 15.20 Poster Discussion 2A Sala Cassiodoro DRUG RESISTANCE, SIGNAL TRANSDUCTION, TARGETED THERAPY Chairmen: V. Agosti (Catanzaro, Italy) – C. Garofalo (Bologna, Italy)

L4 Activation of the MET receptor drives resistance to anti EGFR therapies in colorectal cancerM. Apicella (University of Turin, Italy), S. Corso, A. Bertotti, S. Hobor, E. Bonazzina, A. Sartore-Bianchi, S. Siena, L. Trusolino, A. Bardelli, S. Giordano

L2 Role of Hedgehog pathway in mediating resistance to anti EGFR TKIs in NSCLCF. M. Morgillo, C.D. Della Corte (Second University of Naples, Italy), F.P. Papaccio, D.V. Vitagliano, F.C. Ciardiello

T12 Taxanes enhanced trastuzumab-mediated ADCC of tumor cells through NKG2D mediated NK cell recognition

T. Triulzi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), L. Sfondrini, S. Varchetta, V. Regondi, M. Di Modica, P. Casalini, A. Balsari, G. Bianchi, G. Mariani, E. Tagliabue

T21 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinibR. Rosa (Federico II University of Naples), L. Formisano, C. D’Amato, V. D’Amato, L. Nappi, R. Marciano, L. Raimondo, C. Di Mauro, A. Petrone, A. Servetto, V. Damiano, S. De Placido, R. Bianco



12 13

T6 Histone deacetylase inhibition leads to enhanced sensitization to pemetrexed via induction of apoptosis and autophagy in non–small cell lung tumor modelsM. Di Martile, (Regina Elena National Cancer Institute, Rome, Italy), D. Trisciuoglio, M. Desideri, C. Gabellini, T. De Luca, A. Eramo, R. De Maria, M. Milella, D. Del Bufalo

T10 Anti-tumor activity of a miR-199 dependent oncolytic adenovirusE. Callegari (University of Ferrara, Italy), B. K. Elamin, .L. D’Abundo, M. Negrini, S. Sabbioni

T5 Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies L. Fattore (Sapienza University of Rome, Italy), E. Marra, M. E. Pisanu, A. Noto, C. De Vitis, F. Belleudi, L. Aurisicchio, R. Mancini, M. R. Torrisi, P. A. Ascierto, G. Ciliberto

L7 Molecular Mechanism of Resistance to Afatinib in EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) cell lines and Potential Therapeutic ImplicationsS. Coco (IRCCS, Azienda Ospedaliera Universitaria San Martino, Genoa, Italy), A. Truini, A. Alama, A. Garuti, E. Carminati, G. Barletta, M.G. Dal Bello, C. Genova, E. Rijavec, C. Sini, F. Grossi

N16 Fenretinide (4-HPR) targets parental and cancer initiating medulloblastoma cellsA. Pagani (University of Insubria Varese, Italy), D. Bartolini, A. Bruno, D.M. Noonan, A. Albini


14


55th




15

14.00 ‐ 15.20 Poster Discussion 2B Sala Ibico BIOMARKERS AND THERAPY Chairmen: D. Di Vizio (Los Angeles, USA) – M. Ferracin (Ferrara, Italy)

I3 Functional connection between RAD51 and CCDC6 in homologous recombination directed repair in lung tumors: new therapeutic perspectives?F. Morra (Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy), C. Luise, A. Marinelli, A. Milano, F. Merolla, A. Cerrato, A. Celetti

I5 PARP1 overexpression and miRNA targeting DNA repair: could they be biomarkers of the BRCAness phenotype?S. De Summa (National Cancer Centre “Giovanni Paolo II”, Bari, Italy), R. Pinto, B. Pilato, D. Petriella, K. Danza, E. Mattioli, D. Sambiasi, O. Palumbo, S. Tommasi

P20 miR-205 and Trastuzumab: potential as adjuvant therapeutic tool and predictive biomarkerE. D’Ippolito (Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy), I. Plantamura, M. Giussani, E. Liotti, L. Braccioli, P. Casalini, E. Tagliabue, M. V. Iorio

S4 ImiR: a reliable and accurate pipeline for analysis of small non coding RNA sequencing datastesG. Giurato (University of Salerno, Baronissi, Italy), A. Rinaldi, A. Hashim, M. R. De Filippo, D. Memoli, A. Weisz

I4 The MRN complex is a potential target for the treatment of MYCN amplified NeuroblastomaM. Petroni, F. Sardina (Ospedale Bambino Gesù Rome, Italy), C. Heil, V. Veschi, S. Albini, D. Fruci, A. Gulino, G. Giannini

P32 Class III β-tubulin is overexpressed in ovarian clear cell and serous carcinoma and represents a novel marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupiloneE. Bignotti (University of Brescia, Italy), C. Romani, P. Todeschini, D.M. Roque, S. Bellone, R.A. Tassi, E. Bandiera, L. Zanotti, N. Buza, E. Cocco, T.J. Rutherford, P.E. Schwartz, A. Ravaggi, E. Sartori, A.D. Santin, S. Pecorelli

P31 miRNA signature characterization in round cell myxoid liposarcomas treated with trabectedinM. Di Marino (Mario Negri Institute of Milan, Italy), L. Beltrame, L. Paracchini, R. San Filippo, P. Casali, A. Gronchi, S. Pilotti, C. Romualdi, F. Bozzi, T. Negri, E. Calura, S. Marchini, M. D’Incalci

P36 MicroRNA-10b expression correlates with metastases development and survival in breast cancer patientsR. Barbano, B. Pasculli, V.M. Valori, A. Fontana, M. Copetti, M.L. Poeta, G. Perrone,F. Pellegrini, A. Onetti-Muda, R. Murgo, E. Maiello, V.M. Fazio, P. Parrella (IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy)



14 15

P26 Evaluation of the prognosis role of IGF1R in prostate cancer patients and association with TMPRSS2-ERG statusI. Casanova-Salas (Fundacion Instituto Valenciano de Oncologia, Valencia, Spain), C. Mancarella, J.A. López-Guerrero, K. Scotlandi

15.30 ‐ 18.30 CANCER STEM CELLS Chairmen: A. Morandi (Florence, Italy) - G. Morrone (Catanzaro, Italy)

15.30 - 16.00 The importance of asymmetry for gene expression in the stem cell compartment of human prostate epithelium

N.J. Maitland (York, United Kingdom) Sponsored by EACR

16.00 - 16.30 Stem cells in homeostasis and cancer: the good, the bad and the ugly R. Fodde (Rotterdam, The Netherlands)

16.30 - 17.00 Clinical implications of cancer stem cell hypothesis L. Ricci-Vitiani (Rome, Italy)

17.00 - 17.30 Targeting pancreatic cancer stem cells G. Draetta (Houston, USA)

17.30 - 18.00 Modeling of human leukemias J.J. Schuringa (Groningen, The Netherlands)

18.00 - 18.15 Depletion of HIPK2 full-length protein preserving the ΔE8 isoform triggers E7 apoptosis in colon cancer stem cells in vitro and in vivo G. Di Rocco, V. Gatti, A. Verdina, M. Pietrafesa, G. Toietta, S. Soddu (National Cancer

Institute Regina Elena, Rome, Italy)

18.15 - 18.30 Radiotherapy induced miR expression influences the formation of local R7 recurrence in breast cancer L. Fabris (CRO National Cancer Institute, Aviano, Italy), S. Berton, S. Massarut, S. D’ Andrea, G. Calin, B. Belletti, G. Baldassarre

18.30 ‐ 19.00 AWARD CEREMONY

19.00 ‐ 20.00 siC GenerAl Assembly

20.30 Social Dinner


16


55th




8.15 ‐ 12.30 ANIMAL MODELS OF CANCER Chairmen: R. Dolcetti (Aviano, PN, Italy) - A. Fusco (Naples, Italy)

8.15 - 8.45 Mouse models of glioma subtypes E. Holland (New York, USA)

8.45 - 9.15 The role of hypoxic responses in leukemogenesis R. Bernardi (Milan, Italy)

9.15 - 9.45 Novel players in tumor microenvironment U. Cavallaro (Milan, Italy)


10.15 - 10.45 Application of genomics to zebrafish models in cancer research M.A. Rubin (New York, USA)

10.45 - 11.15 Zebrafish models of cancer M.C. Mione (Eggenstein-Leopoldshafen, Germany)

11.15 - 11.30 AKT1-E17K is oncogenic in mouse and human lung through p27 delocalization A3 C. De Marco (University of Magna Graecia, Catanzaro, Italy) D. Malanga, O. Paciello, S. Papparella, F. Zito Marino, R. Franco, G. Viglietto

11.30 - 11.45 Yes-associated protein is required for the clonal expansion of preneoplastic A6 hepatocytes and oval cell proliferation

M.A. Kowalik (University of Cagliari, Italy), A. Perra, E. Ghiso, G.M. Ledda-Columbano, S. Giordano, A. Columbano

12.00 - 12.30 Epigenomics: functionally indexing genomes in health and disease H. Stunnenberg (Nijmegen, The Netherlands)

12.30 ‐ 13.30 CLOSING LECTURE Chair: R. Dolcetti (Aviano PN, Italy)

From Data to Knowledge: Using ‘omics to drive discovery J. Quackenbush (Boston, USA)

13.30 ‐ 13.45 AWARD FOR THE BEST ORAL SELECTED PRESENTATION

13.45 ‐ 14.00 Closing remarKs

14.00 - 15.00 Lunch

Thursday 26 September SCIENTIFIC PROGRAMME


16 17

CME CreditsNo. 2,5 Italian Ministry of Health CME (Continuing Medical Education) credits for the event on September 23 and No 8 CME credits for the event from September 24 to 26 have been assigned for the following categories:

- Medical Surgeon (Haematology, Medical Genetics, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Clinical Pathology, Internal Medicine)

- Biologist, Pharmacist, Chemist (Analytical Chemistry), Physicist (Health Physics), Veterinary Surgeon

AUDIOVISUAL INSTRUCTIONSA Multimedia Slide Centre is located in the Meeting Venue.ONLY PC DATA PROJECTION IS AVAILABLE DURING THE MEETING.Each room is provided with a laptop. Therefore the use of your personal laptop is not allowed.Special requirements should be communicated to the Organizing Secretariat as soon as possible.Power-Point presentations should be handed to the slide centre one hour before the beginning of the session.

PRIZES

Wednesday September 25:

“Piero Trivella” and “EACR” Prizes to the best posters

“Elena Cappannini” Prize to the best 2012 publication as first author in innovative approaches for cancer treatments

“Pezcoller Foundation” Scholarship

Travel Grants

Thursday September 26:

Award for the best oral selected presentation

Scientific Information

18


55th




DatesCatanzaro, 23 – 26, September 2013

Congress Venue

September 23Università degli Studi “Magna Græcia” di CatanzaroViale Europa88100 Germaneto – Catanzaro

September 24-26Villaggio Guglielmo Congress CenterPiazza Susanna, 188069 Copanello - Catanzarowww.villaggioguglielmo.it

SIC Secretariat

Società Italiana di CancerologiaVia G. Venezian, 1 – 20133 MilanPh. +39 02 2666895 – Fax +39 02 2664342Email: [email protected] – Web site: www.cancerologia.it

Organizing Secretariat

Adria Congrex SrlVia Sassonia, 30 – 47922 Rimini RNPh. +39 0541 305811 - Fax +39 0541 305842E-mail: [email protected] – Web site: www.adriacongrex.it/sic2013 LanguageThe official language of the Meeting is English. Simultaneous translation will not be provided.

BadgesParticipants are kindly requested to wear their badge throughout the Meeting.

Certificates of AttendanceCertificate of attendance is issued on request to all registered participants at the end of the Meeting.

Exhibition and SponsorshipA technical, pharmaceutical and publication exhibition will take place in the Meeting Venue throughout the scientific works. Additional sponsoring opportunities are available. For any information, please contact the Organizing Secretariat Adria Congrex.

General Information

19

Registration Information

Registration Feeson-site registration

SIC MEMBER (*) € 450,00NON SIC MEMBER (**) € 550,00SIC MEMBER UNDER 35 (*) € 280,00NON SIC MEMBER UNDER 35 (**) € 355,00

(*)VAT non applicable as for law ex Art.4 DPR 633/72; (**) VAT 21% includedThe VAT rate will be applied depending on the Italian fiscal law at the time of payment.

Registration fees include: • admission to the scientific sessions• admission to the exhibition area• name badge and congress kit• abstracts book• attendance certificate• ECM certificate• welcome cocktail, coffee breaks, light lunches and social dinner

CancellationIn case of cancellation reimbursement will not be done.

InsuranceRegistration fee does not include insurance of any kind. The Congress Organizers will not be responsible for any participant failing or damages. Any type of insurance should be purchased by congress participants on their own.

2120


55th




A grateful thank to:

I.S.O.

Istituto Superiore di Oncologia

I.S.O.

Istituto Superiore di Oncologia

Centro Interdipartimentale dei Servizi“Genomica e Patologia Molecolare”

Catanzaro


55th




of the italian cancer society -...

Documents